FT Options’s Cascadian Therapeutics, Inc. CASC Stock Holding History

FT Options’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$4K	Buy	+4,000	New	+$15.3K	0.01%	204
2017 Q1	–	Sell	-10,800	Closed	-$3K	–	397
2016 Q4	$3K	Buy	+10,800	New	+$69.8K	﹤0.01%	227
2016 Q3	–	Sell	-8,650	Closed	-$1K	–	472
2016 Q2	$1K	Sell	8,650 -59,383	-87%	-$403K	﹤0.01%	339
2016 Q1	$37K	Buy	+68,033	New	+$524K	0.04%	183

Other funds holding CASC

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return

FT Options's CASC Position: Q3 2017 in Review

FT Options reduced its Cascadian Therapeutics, Inc. (CASC) stake by 9.6% in Q3 2017, selling an estimated $46.8K and leaving 115,206 shares worth $471K. The position accounts for 0.71% of the portfolio, ranked #47.

FT Options first reported a position in CASC in Q4 2015 and has held it in 8 quarters since. The position peaked at $1.5M in Q3 2016. 79 funds tracked by Wall St. Rank hold CASC as of Q3 2017.

FT Options held 115,206 shares of Cascadian Therapeutics, Inc. worth $471K as of Q3 2017.
FT Options sold 12,223 Cascadian Therapeutics, Inc. shares in Q3 2017, an estimated $46.8K.
Cascadian Therapeutics, Inc. made up 0.71% of FT Options's portfolio in Q3 2017, its #47 holding.
FT Options first reported a position in Cascadian Therapeutics, Inc. in Q4 2015 and has held it in 8 quarters since.
FT Options's Cascadian Therapeutics, Inc. position peaked at $1.5M in Q3 2016.
79 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.